NCT06066710 Propranolol in Primary Progressive Aphasia
| NCT ID | NCT06066710 |
| Status | Recruiting |
| Phase | EARLY_Phase 1 |
| Sponsor | University of Missouri-Columbia |
| Condition | Aphasia, Primary Progressive |
| Study Type | INTERVENTIONAL |
| Enrollment | 30 participants |
| Start Date | 2025-01-13 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 30 participants in total. It began in 2025-01-13 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.
Eligibility Criteria
Inclusion Criteria: * 1\. Age: 50 and older * 2\. Primary Progressive Aphasia diagnosis * 3\. Native English speaker Exclusion Criteria: * 1\. Unable to provide consent * 2\. Taking alpha 2 agonists (clonidine and guanfacine) * 3\. Other major psychological or neurological diagnosis * 4\. Major head trauma that contributed to their condition * 5\. Allergic reaction to adhesives * 6\. Uncorrected vision/hearing impairments * 7\. Diabetes * 8\. Reactive airway disease * 9\. Untreated hypothyroidism * 10\. Bradyarrhythmia * 11\. Unexplained syncope * 12\. Pregnancy (assessed verbally on the days of MR imaging) * 13\. Drugs that interact with propranolol, such as alpha 2 agonists * 14\. Claustrophobia, inner ear implants, aneurysm or other surgical clips, metal foreign bodies in eye, pacemaker or other contraindication to MR scanning. Subjects with any implanted device that cannot be verified as MRI compliant will be excluded.
Contact & Investigator
David Beversdorf, MD
PRINCIPAL INVESTIGATOR
University of Missouri-Columbia
Frequently Asked Questions
Who can join the NCT06066710 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Aphasia, Primary Progressive. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06066710 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06066710 currently recruiting?
Yes, NCT06066710 is actively recruiting participants. Contact the research team at beversdorfd@health.missouri.edu for enrollment information.
Where is the NCT06066710 trial being conducted?
This trial is being conducted at Columbia, United States.
Who is sponsoring the NCT06066710 clinical trial?
NCT06066710 is sponsored by University of Missouri-Columbia. The principal investigator is David Beversdorf, MD at University of Missouri-Columbia. The trial plans to enroll 30 participants.